DAVID M MOTT
CIK 1219871 · Vice Chair. of the Board, CEO · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.54B
Companies
38
Total Filings
210
Lifetime Open-Market Net
$324.27M
Filer Profile
Reported Address
1119 ST. PAUL STREETBALTIMORE, MD 21202
Related Filers
FOREST BASKETT — 15 joint filings, latest 2020-02-06
PATRICK J KERINS — 13 joint filings, latest 2020-02-06
SCOTT D SANDELL — 11 joint filings, latest 2020-02-06
NEA 13 GP, Ltd — 10 joint filings, latest 2019-12-18
NEA Partners 13, Limited Partnership — 10 joint filings, latest 2019-12-18
NEW ENTERPRISE ASSOCIATES 13 LP — 10 joint filings, latest 2019-12-18
PETER J BARRIS — 9 joint filings, latest 2019-11-12
NEA 14 GP, LTD — 6 joint filings, latest 2020-02-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVAX | Director | 79,770 | $10.89 | $869.1K | -$6.31M | 11 | 2026-06-23 |
| ARDX | Director | 6,831,841 | $3.54 | $24.22M | $65.06M | 31 | 2026-06-18 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | Director | 0 | $29.08 | $0 | $33.01M | 25 | 2026-01-06 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 19,500,000 | $0.06 | $1.13M | $5.00M | 6 | 2024-07-01 |
| Epizyme, Inc. (EPZM) Delisted | Director | 331,447 | $1.47 | $487.2K | $30.27M | 37 | 2022-07-05 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 57,306 | $14.59 | $836.1K | $313.6K | 6 | 2022-06-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 205,245 | $8.16 | $1.67M | $1.23M | 2 | 2019-12-26 |
| NET | 10%+ Owner | 4,059,376 | $355.17 | $1.44B | $0 | 1 | 2019-09-18 |
| MIRM | 10%+ Owner | 3,736,243 | $91.08 | $340.30M | $6.75M | 1 | 2019-07-24 |
| ASND | Director | 12,000,000 | $236.00 | $2.83B | $49.02M | 8 | 2019-07-03 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 7,225,676 | $0.00 | $4.3K | $14.69M | 2 | 2019-06-25 |
| NITE | Director | 0 | $39.63 | $0 | $0 | 2 | 2019-06-07 |
| TRVI | 10%+ Owner | 2,938,562 | $15.16 | $44.55M | $25.00M | 1 | 2019-05-13 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 2,524,386 | $15.00 | $37.87M | $17.12M | 15 | 2019-04-08 |
| TESARO, Inc. (TSRO) Delisted | Director | 0 | — | — | $73.35M | 10 | 2019-01-22 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | 10%+ Owner | 6,641,634 | $0.07 | $465.6K | $90.00M | 1 | 2018-10-24 |
| ESTC | 10%+ Owner | 4,155,995 | $89.01 | $369.93M | $0 | 1 | 2018-10-10 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 8,949 | $36.92 | $330.4K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 504 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $100.41 | $437.76M | $9.35M | 1 | 2017-10-10 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 2,576,939 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 1,858,450 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,499,166 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 0 | $32.80 | $0 | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 0 | $8.52 | $0 | -$46.25M | 6 | 2014-11-28 |
| DERM | 10%+ Owner | 3,502,922 | $7.33 | $25.68M | $1.11M | 1 | 2014-10-08 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 575 | $0.08 | $47 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 1,171 | $190.47 | $223.0K | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
| MEDI | Vice Chair. of the Board, CEO | 599,355 | $33.23 | $19.92M | $0 | 5 | 2007-06-19 |
Recent Filings · Page 8 of 21
210 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-24 | ARDX | Buy (P) | +4,673 | $31.5K | EDGAR |
| 2020-06-22 | Epizyme, Inc. (EPZM) Delisted | Other (J) | +67,662 | $0 | EDGAR |
| 2020-06-18 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | ARDX | Mixed | +14,074 | $0 | EDGAR |
| 2020-06-02 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-13 | Mersana Therapeutics, Inc. (MRSN) Delisted | Other (J) | +3,190 | $0 | EDGAR |
| 2020-04-09 | Mersana Therapeutics, Inc. (MRSN) Delisted | Buy (P) | +538,599 | $3.01M | EDGAR |
| 2020-04-02 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | +1,512 | $23.5K | EDGAR |
| 2020-03-16 | Enliven Therapeutics, Inc. (IMRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-28 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Buy (P) | +7,500,000 | $5.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.